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Abstract
We examined lateral geniculate nucleus (LGN) degeneration as an indicator for possible diagnosis of glaucoma in
experimental glaucoma monkeys using positron emission tomography (PET). Chronic intraocular pressure (IOP) elevation
was induced by laser trabeculoplasty in the left eyes of 5 cynomolgus monkeys. Glial cell activation was detected by PET
imaging with [
11C]PK11195, a PET ligand for peripheral-type benzodiazepine receptor (PBR), before and at 4 weeks after
laser treatment (moderate glaucoma stage). At mild, moderate, and advanced experimental glaucoma stages (classified by
histological changes based on the extent of axonal loss), brains were stained with cresyl violet, or antibodies against PBR,
Iba-1 (a microglial marker), and GFAP (an activated astrocyte marker). In laser-treated eyes, IOP was persistently elevated
throughout all observation periods. PET imaging showed increased [
11C]PK11195 binding potential in the bilateral LGN at 4
weeks after laser treatment; the increase in the ipsilateral LGN was statistically significant (P,0.05, n=4). Immunostaining
showed bilateral activations of microglia and astrocytes in LGN layers receiving input from the laser-treated eye. PBR-
positive cells were observed in LGN layers receiving input from laser-treated eye at all experimental glaucoma stages
including the mild glaucoma stage and their localization coincided with Iba-1 positive microglia and GFAP-positive
astrocytes. These data suggest that glial activation occurs in the LGN at a mild glaucoma stage, and that the LGN
degeneration could be detected by a PET imaging with [
11C]PK11195 during the moderate experimental glaucoma stage
after unilateral ocular hypertension. Therefore, activated glial markers such as PBR in the LGN may be useful in noninvasive
molecular imaging for diagnosis of glaucoma.
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Introduction
Open-angle glaucoma (OAG) is a slowly progressive and
irreversible ocular disease that is one of the leading causes of
blindness worldwide. Therefore, increasing attention is being paid
to evaluation of the appearance of the optic nerve head and
peripapillary retina in the diagnosis of OAG, especially in its early
stage. Glaucoma pathology has been extensively studied at the
level of the retinal ganglion cells (RGC) and optic nerve, with
diagnosis resulting primarily from intraocular pressure (IOP),
ophthalmoscopic, and visual field measurements. On the other
hand, we and several investigators [1,2,3,4] reported that neuronal
degeneration in the lateral geniculate nucleus (LGN), which is the
primary processing center for visual information received from the
retina, occurred in experimental glaucoma models. Briefly, in
experimental glaucoma monkeys, neuronal atrophy in the LGN
appeared to occur at an early stage after IOP elevation, and LGN
neurons were apparently more susceptible to the effects of IOP
elevation than optic nerve axons [1,2]. Furthermore, Gupta and
her colleagues [5,6] firstly reported that the death of the RGC in
glaucoma patients is accompanied by transsynaptic degradation of
neurons in the LGN. These findings strongly suggest that LGN
degeneration may become new diagnostic and/or therapeutic
targets for glaucoma.
Recently, we demonstrated that glial fibrillary acidic protein
(GFAP) immunoreactivity as well as neuronal cell loss was
increased in the LGN of cynomolgus monkeys at 4 months after
unilateral ocular hypertension [7], and that microglial activation
was detectable by positron emission tomography (PET) imaging
with [
11C]PK11195, a PET ligand for the peripheral-type
benzodiazepine receptor (PBR), at 4 to 12 months after unilateral
ocular hypertension [8]. PBR, also known as translocator protein
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30526(18 kDa) (TSPO) [9], is a highly hydrophobic protein located
primarily on the outer mitochondrial membrane [10]. Although
PBR is expressed at low or reduced levels in resting microglial cells
and astrocytes of the normal brain, it is upregulated in activated
microglial cells and astrocytes [11,12,13]. Thus, noninvasive
molecular imaging of the LGN targeted against activated glial
markers such as PBR may be helpful in the early diagnosis of
glaucoma. However, the courses of glial activation and PBR
expression that accompany LGN degeneration in glaucoma are as
yet unknown.
In the present study, we examined LGN degeneration
secondary to experimental hypertensive glaucoma as an indicator
for glaucoma in ocular hypertensive monkeys using PET, and
validated glial activation by morphological and immunohisto-
chemical examinations.
Materials and Methods
Animals
The 5 adult cynomolgus monkeys (Macaca fascicularis) in this
study, aged 4 to 6 years (Japan SLC Co. Ltd, Hamamatsu, Japan),
were housed in an air-conditioned room at 2462uC with 60610%
humidity, and given food and water ad libitum. The animal welfare
and steps taken to ameliorate suffering were in accordance with
the recommendations of the Weatherall report on the use of non-
human primates in research, and all investigations were approved
and monitored by the Institutional Animal Care and Use
Committee of Kobe Institute in RIKEN (Permit Number:
MAH18-05-15).
Argon-Laser Photocoagulation (Experimental Glaucoma
Model)
An elevation of intraocular pressure (IOP) was induced in each
monkey by applying argon-laser burns to the mid portion of the
trabecular meshwork of the left eye, with the right eye being used
as an untreated control, as previously described [14,15]. The laser
irradiation was performed only on the left eyes, because we
considered that laser irradiation on the ipsilateral eyes under the
same conditions would facilitate accurate irradiation without
technical dispersion. For the laser treatment, the animals were
anesthetized with an intramuscular injection of ketamine
(8.75 mg/kg, Ketalar 50H; Sankyo, Tokyo, Japan) plus xylazine
(0.5 mg/kg, CelactalH; Bayer, Leverkusen, Germany). A single-
mirror Goldmann lens (OSMGA, Ocular Instruments, Inc.,
Bellevue, WA, USA) filled with a hydroxyethylcellulose solution
(ScopisolH15; Senjyu Pharmaceutical, Osaka, Japan) was then
placed on the eye to be treated. An argon blue/green laser was
focused on the mid-portion of the trabecular meshwork, and a
total of 100 to 150 laser-beam spots was applied around 360u (spot
size, 100 mm; power, 1000 mW; exposure time, 0.2 sec) using an
argon-laser photo-coagulator (Ultima 2000 SEH; Coherent, Inc.,
CA, USA) attached to a standard slit-lamp microscope (BQ 900;
Haag-Streit, Ko ¨niz, Switzerland). Two weeks after the first
treatment, the laser treatment was repeated, except for monkey
#5, so as to produce a maintained elevation in IOP. Time (in
weeks) ‘‘after the laser treatment’’ was defined as dating from the
first of these treatments.
IOP and Ophthalmoscopy
IOP was measured in both eyes of each animal using a calibrated
pneumatonometer (Model 30 Classic Pneumatonometer; Medtro-
nic Solan, FL, USA) under ketamine anesthesia (8.75–10 mg/kg,
i.m.), with local anesthesia using 0.4% oxibuprocaine hydrochloride
(BenoxilH 0.4%solution;SantenPharmaceuticalCo.Ltd.).IOP was
measured between 2 p.m. and 4 p.m. at 1- or 2-weeks intervals.
Then, fundus photographs (AFC-210; NIDEK Co. Ltd.
Gamagori, Japan) were obtained under additive injection of
xylazine (0.5 mg/kg, i.m.), and cup/disc (C/D) area ratio was
assessed using data filing and analysis software (NAVIS-Lite ver
1.0.4.1, NIDEK Co. Ltd.). All measurements were taken at one- or
two-week intervals.
PET Imaging for [
11C]PK11195
PET imaging was performed in 4 monkeys (#2t o#5) at 4
weeks after the first laser treatment, but monkey #1 was not
measured the PET imaging, because monkey #1 showed IOP
elevation, but did not change the optic disc. Before PET, a venous
cannula was placed into a radial vain. For the scan, the animals
were placed on the bed in a small animal PET scanner (microPET
Focus220; Siemens Medical Solutions, Knoxville, TN, USA)
under anesthesia with a continuous intravenous infusion of
propofol (10 mg/kg/h, Hospira Japan Co. Ltd., Osaka, Japan).
The spatial resolution at the center of the field of view was
,1.35 mm in full width at half maximum (FWHM). The
[
11C]PK11195 was prepared according to previously described
methods, using the reaction of (R)-N-desmethyl precursor (1 mg) in
dimethylsulfoxide (200 ml) containing 1 mg of KOH, with [
11C]-
CH3I produced by a cyclotron (HM12; Sumitomo Heavy
Industry, Tokyo, Japan) [16]. Radiochemical purities were
.99.5%, and the mean (6 SD) specific activity was 65.9
(629.4) GBq/mmol. After a transmission scan for 30 min with
68Ga-
68Ge pin source, [
11C]PK11195 (187.6622.9 MBq) was
injected as an intravenous bolus, and PET scanning was
performed for 90 min. PET images were acquired with three-
dimensional list mode reconstructed by an algorithm of filtered
back projection (FBP), and were smoothed by a Hanning filter
with a cutoff of 0.4. Attenuation correction, but not scatter fraction
correction, using blank and transmission images, was performed to
obtain quantitative images. A dynamic histogram acquired during
90 min (6610 sec, 6630 sec, 11660 sec, 156180 sec, 36600 sec)
was used for data analysis.
Reconstructed images were processed with PMOD version 3.0
image analysis software (PMOD Technologies, Zu ¨rich, Switzer-
land). To elucidate the quantitative [
11C]PK11195 binding to
PBR in the brain, the cerebellum was used as a reference region to
calculate binding potential value in a simplified reference tissue
model (SRTM) developed by Lammertsma and Hume [17].
Regional binding potential values were obtained by applying some
regions of interest (ROI) to the individual PET images aligned on
individual magnetic resonance imaging (MRI). ROIs were
manually drawn with reference to the stereotaxic brain atlas of
the cynomolgus monkey for the cerebellum and LGN.
MRI was performed for all animals using a 3-T MRI scanner
(Signa Horizon Lx VH3; General Electric Healthcare, Milwaukee,
WI) under pentobarbital anesthesia to define anatomical ROIs in
a separate session from PET imaging.
Histological Examination
After the last measurements, animals were transcardially
perfused to the bilateral common carotid arteries with 2.0 liters
of 0.9% saline containing 10 U/ml heparin at 4uC after ligation of
thoracic aorta., under deep sodium pentobarbital anesthesia
(30 mg/kg, i.v.; Nembutal; Abbott, North Chicago, IL, USA),
followed by 2.0 liters of 4% paraformaldehyde in 0.1 M
phosphate buffer (pH 7.4). The brains and eyeballs with optic
nerve were removed after the perfusion. The brains and eyes were
cut into several sections and immersed in the same fixative solution
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embedding compound (Tissue-Tek; Sakura Finetechnical Co.
Ltd., Tokyo, Japan). Next, 20-mm thick coronal sections of the
LGN and retina were serially cut, then stained with cresyl violet or
hematoxylin and eosin, respectively. Retinal damage was evalu-
ated as follows: six sections stained with hematoxylin and eosin
from each eye being used for the morphometric analysis. Light-
microscope photographs were taken using a digital camera a
charge-coupled device camera (MicroPublisher 5.0RTV, QIMA-
GING, Burnaby, BC, Canada), and the cell counts in the ganglion
cell layer (GCL) and inner nuclear layer (INL) at a distance
between 1750 and 2200 mm from the optic disc were measured on
the images in a masked fashion by a single observer (Y. I.). Data
from six sections were averaged for each eye, and the values
obtained were used to evaluate the GCL and INL cell counts.
To assess number and size of neurons in the LGN, sections
stained with cresyl violet were used for these measurements: The
measurements were performed on three sections representative of
the anterior, middle, and posterior parts of each LGN. The
volume used for the measurements was 2166162620 mm (section
thickness) of each side in the LGN. Care was taken to count only
neurons with clearly visible nuclei and cytoplasm. For quantifica-
tion of cresyl violet-stained sections, neuron numbers in the M-
and P-layers were estimated by counting under objective640 with
brightfield microscope in a masked fashion by a single observer
(Y.I.). The number on each section was measured using image-
processing software (Image-J ver. 1.33f; National Institutes of
Health, USA). Neuron counts were derived from three regions per
layer in each of the three LGN sample sections. The effects of
elevated IOP on neuronal cell size were studied by measuring
1200 geniculate neurons in each animal. Neuron samples (100
neurons/layer) were taken randomly from the full width of each
lamina and included only those neurons with clearly visible
nucleoli, and measured soma area. Average neuronal cell size for
each layer was calculated on the basis of data from 100 neurons.
Segments of optic nerve from 3 mm behind the eye were
postfixed by immersion in 1.25% glutaraldehyde with 2%
paraformaldehyde in PBS for at least 1 week at 4uC. After three
washes with PBS, the nerve segments were placed in 2% osmium
tetroxide in saline for 2 h, then washed with PBS at room
temperature. Subsequently, they were dehydrated in alcohol and
embedded as cross-sections in epoxy resin for sectioning. Cross-
sections (1 mm thickness) were cut with an ultramicrotome,
mounted on glass slides, and stained for myelin using 1% toluidine
blue. For counting of the numbers of RGC axons, the optic nerve
area was divided into five segments (nasal, temporal, superior,
inferior and central) in each optic nerve sections. We captured
thirteen images from these segments in each optic nerve at high
power using an oil immersion objective 6100 with bright-field
microscope completed with wide field and high resolution CCD
camera (BZ-9000, KEYENCE CORPORATION, Osaka, Ja-
pan),. In each image (1456109 mm), every myelinated axon was
counted in masked fashion by a single observer (T.N.) and the data
from the thirteen images were summed. Estimated total area was
covered more than 3% per nerve, according to the previous report
[18]. Axon number was expressed as (healthy axon number on left
side)/(healthy axon number on right side)6100% for each animal.
Glaucoma stages were classified by the extent of axonal loss as
mild (0–20%), moderate (20–50%), and advanced (50–100%)
(Table 1).
Immunohistochemistry
During the immunostaining procedures, coronal sections con-
taining LGN were washed with 0.01 M phosphate-buffered saline
(PBS, pH 7.4), then treated with 0.3% hydrogen peroxide in
0.01 M PBS. They were then preincubated with 10% normal goat
serum (Vector, Burlingame, CA, USA) in 0.01 M PBS for 30 min
and incubated for one day at 4uC with specific mouse anti-glial
fibrillary acidic protein (GFAP) monoclonal antibody (1:800
dilution) (MAB360; Chemicon, Temecula, CA, USA), rabbit anti-
ionized calcium-binding adaptor molecule 1 (Iba-1) polyclonal
antibody (1: 600 dilution) (019-19741;Wako, Osaka, Japan) in a
solution of 10%normal goat serum in 0.01 M PBScontaining0.3%
(v/v) Triton X-100. The coronal sections were then washed with
PBS and incubated with biotinylated anti-mouse or anti-rabbit IgG
before being incubated with avidin-biotin-peroxidase complex for
30 minatroomtemperature.Finally,diaminobenzidinewasusedas
a peroxidase substrate for visualization. To assess area of GFAP and
Iba-1 immunoreactivity in the LGN, sections immunostained with
GFAP or Iba-1 were used for the area measurements: The
measurements were performed on three sections representative of
the anterior, middle, and posterior parts of each LGN. The volume
used for the area measurements was 2166162620 mm (section
thickness) of each side in the LGN. The measurements were carried
out under objective 640 with brightfield microscope in a masked
fashion by a single observer (Y.I.). The area on each section was
Table 1. Changes in IOP and the optic disc in cynomolgus monkeys after laser-photocoagulation.
Glaucomatous left eye
No. Baseline D Mean Max. Integral C/D area Glaucoma
IOP (weeks) IOP IOP DIOP ratio stages
(mmHg) (mmHg) (mmHg) (left eye)
RL Pre End
#1 22.6 24.3 9 40.2 52.7 1109.5 0.19 0.20 Mild
#2 21.7 23.4 4 61.3 72.0 475.7 0.25 0.40 Moderate
#3 21.0 20.3 11 60.2 73.3 2501.9 0.17 0.64 Advanced
#4 24.3 24.7 15 62.1 70.7 3267.8 0.19 0.56 Advanced
#5 24.8 22.4 24 50.8 60.0 4450.8 0.23 0.77 Advanced
C/D area ratio: cup/disc area ratio, ONH: Optic nerve head, IOP: Intraocular pressure, R: right eye, L: left eye, D: Duration, Max IOP: Maximum IOP, Integral DIOP: Integral
IOP to right eye (D mmHg/day). Glaucoma stages were classified by histological changes based on the extent of axonal loss as mild (0–20%), moderate (20–50%), and
advanced glaucoma (50–100%).
doi:10.1371/journal.pone.0030526.t001
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vale, CA , USA). Data from each section was averaged for each
LGN, and the values obtained were used to evaluate the area of
GFAP and Iba-1 immunoreactivity.
Immunofluorescence Staining
During the immunofluorescence staining procedures, coronal
sections containing LGN were subjected to antigen retrieval by
autoclaving in 0.01 M sodium citrate buffer, pH 6.0, at 121uC for
15 min. Next, they were preincubated with 10% normal goat
serum (Vector) in 0.01 M PBS for 30 min, then incubated for one
day at 4uC with specific rabbit anti-peripheral benzodiazepine
receptor (PBR) polyclonal antibody (1:1000 dilution) in a solution
of 10% normal goat serum in 0.01 M PBS containing 0.3% (v/v)
Triton X-100. We raised a rabbit polyclonal antibody against the
peptide residues 36–47 of mouse PBR (SLQKPSWHPPRW),
designated NP36, and purified it with an antigen peptide affinity-
column to ensure reactivity against the antigen. After washing with
0.01 M PBS, the sections were incubated for 3 h at room
Figure 1. Ocular fundus photographs and histological sections of the retina at each experimental glaucoma stage in laser-treated
eyes of cynomolgus monkeys. (A) Ocular fundus photographs were taken just before the end of the experiment for each monkey Each scale bar
indicates 200 mm for ONH and retina. (B) The cell numbers in ganglion cell layers (GCL) of each experimental glaucoma stage were estimated by
counting GCL cells at a distance between 1750 and 2200 mm from the optic disc. Cell number was expressed as (healthy cell number on GCL of left
eye)/(healthy cell number on GCL of right eye)6100% for each animal.
doi:10.1371/journal.pone.0030526.g001
Table 2. Pathological changes in cynomolgus monkeys after
laser-photocoagulation.
No. Glaucoma RGC Neuronal loss
Immunoreactivity in LGN
layers
stages loss in LGN layers GFAP Iba-1 PBR
#1 Mild + 2 + + +++
#2 Moderate ++ + +++ ++ +++
#3 Advanced +++ +++ +++ +++ +++
#4 Advanced +++ +++ +++ +++ +++
#5 Advanced +++ +++ +++ ++ +++
LGN: lateral geniculate layer, ONH: optic nerve head, ON: optic nerve, GFAP:
glial fibrillary acidic protein, Iba-1: ionized calcium-binding adaptermolecule-1,
PBR: peripheral benzodiazepine receptor. Glaucoma stages were classified by
histological changes based on the extent of axonal loss as mild (0–20%),
moderate (20–50%), and advanced glaucoma (50–100%). Neuronal atrophy,
RGC loss and immunoreactivity were classified based on the quantitative data
as follows: no changes; 2, mild; +, moderate; ++, robust; +++.
doi:10.1371/journal.pone.0030526.t002
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fragment of goat anti-rabbit IgG (H+L) (1:1000 dilution) (A11070;
Invitrogen, Carlsbad, CA, USA). To assess number of PBR-
positive cell in the LGN, sections immunostained with PBR were
used for the number measurement: The Measurement were
performed on three sections representative of the anterior, middle,
and posterior parts of each LGN. The volume used for the
measurements was 2166162620 mm (section thickness) of each
side in the LGN. The measurements were carried out under
objective 640 with brightfield microscope in a masked fashion by
a single observer (Y.I.). The number on each section was measured
using image-processing software (Image-J ver. 1.33f; National
Institutes of Health, USA). Data from each section was averaged
for each LGN, and the values obtained were used to evaluate the
number of PBR-positive cell.
Retinal sections were preincubated with 10% normal horse
serum and (Vector) and 0.3% TritonX100 in 0.01 M PBS for
30 min, then incubated for one day at 4uC with mouse anti-
calbindin mAb (1:200 dilution) (Abcam, Cambridge, MA, USA),
rabbit anti-calretinin mAb (1:200 dilution) (Abcam), mouse anti-
parvalbumin mAb (1:1000 dilution) (Millipore, Temecula, CA,
USA) or and goat anti-Brn3a (1:1000 dilution) (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), in a solution of 10%
normal horse serum in 0.01 M PBS containing 0.3% (v/v) Triton
X-100. After washing with 0.01 M PBS, the sections were
incubated for 3 h at room temperature with a mixture of
AlexaFluor 546 labeled rabbit anti-goat IgG (1:1000 dilution)
(Invitrogen) and AlexaFluor 488 labeled rabbit anti-mouse
IgG(F(ab9)2) (1:1000 dilution) (Invitrogen), or with a mixture of
AlexaFluor 546 labeled donkey anti-rabbit IgG (1:1000 dilation)
(Invitrogen) and AlexaFluor 488 labeled donkey anti-goat IgG
(1:1000 dilution) (Invitrogen) in PBS with 10% normal horse
serum and 0.3% TritonX100 and Hoechst33342 (1:5000 dilution)
(Invitrogen) for 3 h at room temperature. Immunofluorescence
Figure 2. Optic nerve degeneration at each experimental glaucoma stage in laser-treated eyes of cynomolgus monkeys. (A) Optic
nerve were cut with an ultramicrotome, mounted on glass slides, and stained for myelin using 1% toluidine blue. Each scale bar indicates 1000 mm
(low magnification images) and 10 mm (high magnification images), respectively. (B) The axonal numbers in optic nerve (ON) of each experimental
glaucoma stage were estimated by counting myelinated axons in each segment 145610961 mm (section thickness). Axon number was expressed as
(healthy axon number on left side)/(healthy axon number on right side)6100% for each animal.
doi:10.1371/journal.pone.0030526.g002
An Alteration in LGN of Glaucoma Monkeys
PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e30526images were taken using a microscope (BX50; Olympus, Tokyo,
Japan) with a cooled charge-coupled device camera (DP30BP;
Olympus) at 136061024 pixels via MetaMorph software (Molec-
ular Devices), and the calbindin-positive cells were counted in the
inner part of inner nuclear layer (INL) at a distance between 1750
and 2200 mm from the optic disc on the images in a masked
fashion by a single observer (M.S.).
Double Immunofluorescence Staining
To confirm the cell phenotypes containing PBR, we performed
double immunofluorescence staining for PBR and GFAP or Iba-1
on LGN sections. Coronal sections containing LGN were
prepared as described above.
To visualize co-localization of PBR with GFAP, the sections
were incubated overnight at 4uC with rabbit anti-PBR polyclonal
antibody (1:1000 dilution) and mouse anti-GFAP monoclonal
antibody (1:800 dilution) in a solution of 10% normal goat serum
in 0.01 M PBS with 0.3% (v/v) Triton X-100. Next, they were
washed with 0.01 M PBS and then incubated for 3 h at room
temperature with a mixture of an Alexa Fluor 488 F(ab9)2
fragment of goat anti-rabbit IgG (H+L) (1:1000 dilution)
(Molecular Probes) and an Alexa Fluor 546 F(ab9)2 fragment of
goat anti-mouse IgG (H+L) (1:1000 dilution) (A-11018; Molecular
Probes). Co-localization of PBR with Iba-1 was visualized by
double immunofluorescence staining on LGN sections. The
sections were incubated with a primary antibody for PBR (1:500
dilution) labeled with Zenon Alexa Fluor 488 (Z25302; Molecular
Probes), and with a primary antibody for Iba-1 (1:300 dilution)
with Zenon Alexa Fluor 594 (Z25207; Molecular Probes,) for 3 h
at room temperature.
Data Analysis
Data are expressed as mean 6 S.E.M. A paired t-test was used
to compare [
11C]PK11196 binding potential between before and 4
weeks after the laser treatment. Pearson correlation coefficient was
calculated between the mean PBR-positive cell numbers in LGN
layers receiving input from glaucoma eye and the percent changes
of GFAP-, Iba-1-immunoreactivities, soma size in LGN, or
percent change of axon numbers in optic nerve in each of five
glaucoma monkeys. Results were considered significantly different
if P,0.05.
Results
Fundus Images and Retinal Damage after IOP Elevation
The mean IOP value in 10 eyes of 5 normal cynomolgus
monkeys examined in this study was 22.960.7 mmHg (n=5) in
the right eye and 23.060.8 mmHg (n=5) in the left eye. The IOP
data are summarized in Table 1. There were no significant
changes (p.0.05) between the two eyes. The IOP of the monkeys
was elevated and remained above baseline throughout the
observation period (4–24 weeks) after the first laser treatment.
Figure 3. Changes in optic disc and [
11C]PK11195 PET image in coronal slices from cynomolgus monkeys at a moderate stage after
laser photocoagulation. (A) Accumulation of [
11C]PK11195 binding potential in the LGN before and 4 weeks after laser photocoagulation. Coronal
planes at the level of the LGN are shown. The PET images are shown in color, overlaid on the template MRIs is shown in gray scale. The color scale on
the right represents standard uptake value (SUV). (B) Binding potential values of the right and left LGN obtained from 4 different individuals (4
monkeys; #2, #3, #4, #5, seen in tables 1 and 2). White and black column indicate pretreatment (pre) and post treatment (post) periods,
respectively, for the laser photocoagulation. Each column represents the mean 6 S.E.M. (n=4). *p,0.05 versus the pretreatment.
doi:10.1371/journal.pone.0030526.g003
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but it was lower in monkey #1 than other 4 monkeys. No obvious
retinal lesions, nerve fiber layer defects, or abnormalities of either
the optic nerve head or vascular structures were observed in any of
the eyes before laser irradiation. Ocular fundus photographs of
laser-treated eyes at each glaucoma stage are shown in Fig. 1A.
Figure 4. The expression of peripheral benzodiazepine receptor (PBR) in LGN layers receiving input from a glaucomatous eye. Each
experimental glaucoma stage was classified by the glaucoma severity based on the extent of axonal loss as mild (0–20%), moderate (20–50%), and
advanced (50–100%). (A) Representative photographs of PBR-positive cells in LGN layers of the contralateral (Contra) and ipsilateral (Ipsi) sides are
shown for each experimental glaucoma stage. Layers 1 (L1) and 4 (L4) on the contralateral side receive their innervations from the glaucomatous (left)
eye, whereas L1 and L4 on the ipsilateral side receive their retinal inputs from the non-treated fellow (right) eye. Each scale bar indicates 50 mm. (B)
The numbers of PBR-positive cells on each section were measured, and averaged for each LGN as mean 6 S.E.M. at each M-(layers 1 and 2) and the
P-(layers 3–6) layers.
doi:10.1371/journal.pone.0030526.g004
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extent of IOP elevation and duration after laser irradiation (Fig. 1A
and Table 1). The cell numbers in GCL and myelinated axon in
the optic nerve (ON), but not the cell number in INL, were also
decreased depending on the extent of IOP elevation and duration
(Figs. 1B, 2 and Table 2): the cell number of GCL was 88.5, 77.9,
35.8, 24.0, and 11.7% of that in the contralateral control GCL of
monkey #1t o#5, respectively, the cell number of INL was 102.3,
104.8, 97.9, 99.1, 98.9% of that in the contralateral control INL of
monkey #1t o#5, respectively , and the mean axonal number in
the (left) ON was 93.7, 58.9, 42.2, 26.8, and 24.4% of that in the
contralateral control (right) ON of monkey #1t o#5, respectively.
On the other hand, a monkey #1 defined as mild glaucoma stage
(Table 1) showed a persistent IOP elevation, but there was slight
optic disc change based on ophthalmoscopy during 9 weeks.
Therefore, histological analysis was performed in this monkey at 9
weeks after the laser treatment, and focal degeneration of the optic
nerve was observed at the peripheral region (89.1% of the axon
number in the fellow ON), but not at the central region (102.4% of
the axon number in the fellow ON) (Fig. 2).
[
11C]PK11195 Binding in LGN before and during the
moderate stage of glaucoma after Laser Treatment
We measured binding potential value of [
11C]PK11195 in the
brain before and during the moderate stage of glaucoma based on
ophthalmoscopy (at 4 weeks) after the laser treatment in 4
cynomolgus monkeys. Representative PET images in a moderate
glaucoma monkey are shown in Fig. 3A. At the moderate stage of
glaucoma, mean cup/disc area ratio was 0.4360.02 (monkeys #2
to #5, n=4) against 0.2160.02 (n=4) before the laser treatment. In
the PET study, [
11C]PK11195 binding potential value was
significantly increased in the ipsilateral LGN during the moderate
glaucoma stage after unilateral ocular hypertension compared to
before the laser treatment (Fig. 3B). In contrast, in the contralateral
LGN, [
11C]PK11195 bindingpotential value tended to increase but
the differences were not statistically significant (p=0.278, Fig. 3B).
Expression of the Peripheral Benzodiazepine Receptor
(PBR) in the LGN at Each Experimental Glaucoma Stage
To examine the expression of PBR in the LGN at each
experimental glaucoma stage, we used antibodies against PBR
(Fig. 4). PBR-positive cells were observed in the LGN layers
(including both magnocellular- and parvocellular-layers) receiv-
ing input from laser-treated eyes at all experimental glaucoma
stages, and PBR was expressed even at the mild glaucoma stage
(Fig. 4 and Table 2). On the other hand, no PBR-positive cells
were observed in the LGN layers receiving input from non-
treated fellow eyes. Furtheremore, there was no fluorescence
detected from negative controls without anti-PBR antibody
(Fig. 4A).
To identify PBR-positive cells in the LGN, double immunoflu-
orescence staining was performed for PBR and Iba-1 or for PBR
and GFAP (Fig. 5). PBR-positive cells were co-labeled in a portion
of the Iba-1-positive microglial cells and GFAP-positive astroglial
cells in the LGN at both moderate (monkey #2) and advanced
glaucoma (monkey #5) stages (Fig. 5).
Histological Changes and Glial Activation in LGN at Each
Experimental Glaucoma Stage
To examine the histological and pathological changes in the
LGN at each stage of experimental glaucoma, coronal sections
including the LGN were stained with cresyl violet, and for
antibodies against PBR, ionized calcium-binding adaptor molecule
1 (Iba-1; a microglial marker), and glial fibrillary acidic protein
(GFAP; an activated astrocyte marker) (Figs. 6, 7, 8 and Table 2).
Cresyl violet staining showed that the number of neuron and
neuronal size in the LGN layers (1, 4 and 6 on the contralateral,
and 2, 3 and 5 on the ipsilateral) receiving input from the laser-
treated eyes were decreased at advanced glaucoma stages
(monkeys #3, #4, and #5), but no changes were seen in the
LGN layers receiving input from the fellow eye (Fig. 6). No
morphological changes including cell number and cellsize were
seen in any LGN layers receiving input from eye in the mild
Figure 5. Double-immunofluorescence staining for PBR with a microglial marker (Iba-1) or a reactive astrocyte marker (GFAP). Layer
1 (L1) on the contralateral side receive their innervations from the glaucomatous (left) eye, whereas L1 on the ipsilateral side receive their retinal
inputs from the non-treated fellow (right) eye. Each scale bar indicates 50 mm.
doi:10.1371/journal.pone.0030526.g005
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PLoS ONE | www.plosone.org 9 January 2012 | Volume 7 | Issue 1 | e30526glaucoma (monkey #1), but neuronal size was slightly decrease in
the magnocellular (M) layer, but not parvocellular (P-) layer, of
LGN receiving input from eye in the moderate glaucoma (monkey
#2) stage (Fig. 6).
We next tested glial activation in the LGN after laser irradiation
(Figs. 7, 8 and Table 2). Numbers of GFAP-positive astroglial cells
(Fig. 7) and Iba-1-positive microglial cells (Fig. 8) were increased in
the LGN layers receiving input from laser-treated eyes compared
to the LGN layers receiving input from the fellow eyes. These
changes depended on the extents of RGC and optic nerve losses
after laser irradiation (Figs. 1, 2 and Table 2). Even at the mild
glaucoma stage, GFAP-positive astroglial cells and Iba-1-positive
microglial cells were increased in the bilateral LGN (Figs. 7 and 8).
Next, we performed Pearson correlation coefficient analysis
between PBR and GFAP, Iba-1, LGN degeneration (soma size), or
optic nerve axons (a glaucoma severity) in each of five glaucoma
monkeys. The correlation coefficients between the mean PBR-
positive cell numbers in LGN layers receiving input from
glaucoma eye and percent changes of GFAP-, Iba-1-immunore-
activity, or soma size in LGN, or optic nerve axons were 0.512
(P=0.378, n=5), 0.064 (P=0.918, n=5), 20.199 (P=0.748,
n=5), and 20.426 (P=0.475, n=5), respectively. In these
comparisons, some parameters showed higher correlation coeffi-
cients of 0.512 (between PBR and GFAP) and 20.426 (between
PBR and optic nerve axons) than other parameters, but did not
show any significance. On the other hand, there was a significant
correlation (r=0.923, P=0.025, n=5) between percent changes of
axon numbers in optic nerve and soma size in LGN.
Discussion
In the present study, we demonstrated that binding potential
value for [
11C]PK11195 was increased in the LGN of unilateral
hypertensive monkeys at a moderate experimental glaucoma stage
(at 4 weeks after laser treatment). PBR was persistently expressed
in glial cells of the LGN receiving input from laser-treated eye in
mild through advanced stages of experimental glaucoma.
In experimental glaucoma, axonal injury in the lamina results in
rapid Wallerian degeneration of the distal axon prior to the death
of the RGC cells [19]. Howell et al. [20] have also reported that
the distal axons are more vulnerable than the RGC soma and
proximal axons in a mouse model of glaucoma (DBA/2J). In the
present study, a mild glaucoma monkey with slight increase of disc
cupping and a moderate glaucoma monkey with mild increase of
disc cupping showed mild and moderate axonal degeneration,
respectively, in the optic nerve, but RGC losses were a modest.
Thus, the axonal injury is more severe than RGC loss during
moderate glaucoma stage. These data strongly support the idea
that the axonal injury is an initial key step in glaucoma, and
therefore the loss of the RGC soma may be preceded by axonal
degeneration. The RGC is known to die by apoptosis in glaucoma
[21,22], but the precise mechanism underlying the transsynaptic
degeneration of the retinogeniculate pathways remains unknown.
Recently, evidences have been growing that the atrophy of the
LGN neuron occurs in experimental primate [1,2,3] and human
glaucoma [5,6]. In primate glaucoma, we and others have
reported that the neuronal shrinkage within LGN occurs at an
early phase after IOP elevation [1,2,3]. In the present study, there
was a significant correlation (r=0.923, P=0.025) between axonal
degeneration in optic nerve and neuronal atrophy in LGN. These
findings indicate that the decreased input from the retina to LGN
is caused by optic nerve dysfunction and/or degeneration. This
type of neurodegeneration starts at the axon terminals and
progresses to the cell bodies. In the present study, activation of
microglia and astrocytes was observed bilaterally in the LGN
layers receiving input from the treated eye and even at the mild
glaucoma stage. These results were also consistent with our
previous reports that showed immunoreactivity with GFAP and
major histocompatibility complex Class II CR3/43 [23], which
are antigens specifically expressed in activated microglia, were
elevated in the bilateral LGN and confined to the LGN layers
receiving input from the affected eye [7,8]. On the other hand,
Lam et al. [24] have reported that GFAP immunoreactivity was
elevated in the LGN layers receiving input from the treated eye
after unilateral optic nerve transection or ocular hypertension in
monkeys, but found no microglial activation with Mac-1
immunoreactivity in the LGN after ocular hypertension. In this
study, we used an antibody which recognized Iba-1 as a microglia
marker, and demonstrated microglia activation in the bilateral
LGN receiving input from the laser-treated eye as well. Iba-1 is
specifically expressed in macrophages/microglia and is upregu-
lated during the activation of these cells. Unlike CR3/43 or Mac-
1, Iba-1 is also expressed in ramified microglia (resting form).
Therefore, this antibody could be highly sensitive and morpho-
logically distinguish between activated and resting microglia.
Accordingly, this discrepancy may be due to the differences of
sensitivity among antibodies used in each experiment, but further
study is needed. Nevertheless, the findings suggest that the glial
activation may become a promising hallmark for early diagnosis
and determination of severity of glaucoma.
A non-invasive PET imaging with [
11C]PK11195 for activated
microglial cells has been extensively used in several neurodegenerative
disorders, such as multiple sclerosis [25], Alzheimer disease [26],
Parkinson disease [27], and Huntington disease [28]. Although PBR
is expressedat low levels in resting microglial cells and astrocytes of the
normal brain, it is upregulated in activated microglial cells and
astrocytes [11,12,13]. Previously, we found that [
11C]PK11195
binding potential value in PET imaging was detected in the bilateral
LGN during the advanced glaucoma stage (4 to 12 months) after
unilateral ocular hypertension in cynomolgus monkeys [8]. In the
present study, we could detect the increase of [
11C]PK11195 binding
potential value in the LGN during the moderate stage of glaucoma
after unilateral ocular hypertension. Briefly, [
11C]PK11195 binding
potential values in 4 cynomolgus monkeys were significantly increased
in the ipsilateral LGN at 4 weeks after unilateral ocular hypertension
compared to before the laser treatment. In the contralateral LGN,
[
11C]PK11195 binding potential values tended to increase, but the
Figure 6. Histological changes in LGN neurons of cynomolgus monkeys after laser photocoagulation. (A) Representative
microphotographs of cresyl violet-stained coronal sections of LGN on the contralateral and ipsilateral sides for each experimental glaucoma
stage. Each experimental glaucoma stage was classified by the glaucoma severity based on the extent of axonal loss as mild (0–20%), moderate (20–
50%), and advanced (50–100%). Layer 1 on the contralateral side and layer 2 on the ipsilateral side receive their innervations from the glaucomatous
(left) eye (shown in bold frame), whereas layer 1 on the ipsilateral side and layer 2 on the contralateral side receive their retinal inputs from the non-
treated fellow (right) eye. L1 and L2: layer 1 and 2. Scale bars indicate 1000 mm in whole LGN image and 50 mm in enlarged image. Neuron number (B)
and mean neuronal cell size (C) in each layer of LGN were measured and averaged as mean 6 S.E.M. at each M-(layers 1 and 2) and the P-(layers 3–6)
layers.
doi:10.1371/journal.pone.0030526.g006
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PLoS ONE | www.plosone.org 10 January 2012 | Volume 7 | Issue 1 | e30526Figure 7. Astrocyte activation in LGN layers receiving input from a glaucomatous eye. (A) Representative photographs of GFAP
immunoreactivity in LGN of the contralateral and ipsilateral sides are shown for each experimental glaucoma stage. Each experimental glaucoma
stage was classified by the glaucoma severity based on the extent of axonal loss as mild (0–20%), moderate (20–50%), and advanced (50–100%).
Layer 1 on the contralateral side and layer 2 on the ipsilateral side receive their innervations from the glaucomatous (left) eye (shown in bold frame),
whereas layer 1 on the ipsilateral side and layer 2 on the contralateral side receive their retinal inputs from the non-treated fellow (right) eye. L1 and
L2: layer 1 and 2. Scale bars indicate 1000 mm in whole LGN image and 50 mm in enlarged image. (B) The GFAP-immunoreactive area on each section
was measured, and averaged for each LGN as mean 6 S.E.M. at each M-(layers 1 and 2) and the P-(layers 3–6) layers.
doi:10.1371/journal.pone.0030526.g007
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PLoS ONE | www.plosone.org 11 January 2012 | Volume 7 | Issue 1 | e30526Figure 8. Microglial activation in LGN layers receiving input from a glaucomatous eye. (A) Representative photographs of Iba-1
immunoreactivity in LGN of the contralateral and ipsilateral sides are shown for each experimental glaucoma stage. Each experimental glaucoma
stage was classified by the glaucoma severity based on the extent of axonal loss as mild (0–20%), moderate (20–50%), and advanced (50–100%).
Layer 1 on the contralateral side and layer 2 on the ipsilateral side receive their innervations from the glaucomatous (left) eye (shown in bold frame),
whereas layer 1 on the ipsilateral side and layer 2 on the contralateral side receive their retinal inputs from the non-treated fellow (right) eye. L1 and
L2: layer 1 and 2. Scale bars indicate 1000 mm in whole LGN image and 50 mm in enlarged image. (B) The Iba-1-immunoreactive area on each section
was measured, and averaged for each LGN as mean 6 S.E.M. at each M-(layers 1 and 2) and the P-(layers 3–6) layers.
doi:10.1371/journal.pone.0030526.g008
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that metabolic activity using 2-[
18F]fluoro-2-deoxy-glucose (
18FDG)
uptake during monocular viewing was significantly reduced in the
ipsilateral visuocortical areas of the glaucoma eye [8]. Taken together,
this asymmetry might suggest that visual field defects in the nasal area
and the corresponding RGC and optic nerve damage in the temporal
r e t i n aa r em o r es e v e r et h a na r et h o s eo nt h eo p p o s i t es i d e .
In the present study, we demonstrated for the first time that
PBR-positive cells occurred in the LGN layers (including both
magnocellular- and parvocellular-layers) that received input from
laser-treated eyes at all glaucoma stages. Interestingly, PBR
expression was even observed at the mild glaucoma stage with
slight increase of disc cupping based on ophthalmoscopy. A
portion of the PBR-expressing cells were also with Iba-1-positive
microglial cells and GFAP-positive astroglial cells. These data
provide further evidence that PBR is persistently expressed in glial
cells of the LGN that receive input from the laser-treated eye in
mild through advanced stages of glaucoma. In contrast to the
asymmetry seen for [
11C]PK11195 binding potential values
between bilateral LGN, Iba-1- , GFAP-, or PBR-positive glial
cells showed no similar asymmetry in the bilateral LGN. In the
PET imaging, living monkeys were used and, therefore, some
differences of biological or haemodynamic activities such as
cellular activity and blood flow between the bilateral LGN might
be affected to PK11195 binding potentials, but further studies will
be needed to explain this discrepancy.
Recently, reduction of functional activity in the primary visual
cortex has been reported in open-angle glaucomatous patients
with asymmetric visual field damage by using fMRI technique
[29,30], though the result of the correlation between fMRI
responses and measurements of optic disc damage is still
controversial in these studies. There may be strong plasticity and
compensatory mechanism of the visual pathway during early stage
of diagnosis progression, which makes difficult to use the activity
related fMRI signal for identifying the early indicators of
glaucoma. Though MRI scans have generally higher spatial and
temporal resolutions than PET, and allows functional assessment
of the region brain without any imaging agents, the PET imaging
technique has higher sensitivity and specificity to the biological
process in the specific cell, PBR in the activated glial cells in this
case, which has not been available by MRI technique yet.
Therefore, at present PET imaging has more reliable with sensitive
and specific values for diagnosing glaucoma especially in the early
stage. Furthermore, PET imaging may have more sensitive and
specific value for diagnosing glaucoma especially in the early stage.
In conclusion, these findings indicate that non-invasive
molecular imaging of the LGN targeted against activated glial
markers such as PBR may be useful in diagnosis of glaucoma and
in the development of neuroprotective agents. However, in the
present study the sample size was small at each stage of glaucoma
and, therefore, further additional studies will be needed.
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